Except that quality-adjusted life expectancy changes due to side effects of drugs are valued much more higher than people dying due to being too broke to get any non-ER-care for acute, but not yet emergency-posing illnesses. Even within the drug certification process there is an issue with relatively niche drugs wasting a lot on overly-extensive studies, if you calculate how many people would get how much benefit from getting/affording these niche drugs. IIRC there is about an order of magnitude higher weight on side-effect deaths compared to lack-of-medicine deaths for niche drugs.